Ladenburg Thalmann Downgrades XTL Biopharmaceuticals (XTLB) to Sell
More News related to XTLB
- XTL Biopharmaceuticals (XTLB) Slashes 75% of Workforce
- Unusual 11 Mid-Day Movers 11/18: IDMI, PSUN, DHT, CQB Higher; XTLB, NCOC, SKS, DIVX Lower
- Ladenburg Thalmann Downgrades XTL Biopharmaceuticals (XTLB) to Sell
- Pre-Open Movers: Winnebago (WGO) Sinks On Poor Results, Borders (BGP) Up On Earnings/Strategic Review
- XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre-Clinical Program in Hepatitis C to Presidio
More News related to Downgrades
- Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
- Adams Resources & Energy (AE) Announces Activity At Haynesville Shale
Ladenburg Thalmann downgrades XTL Biopharmaceuticals (Nasdaq: XTLB) from Buy to Sell.
XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of diabetic neuropathic pain and hepatitis C.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
